Taxotere Prostate Cancer New Indication Registration Trial in China
To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and prednisone in subjects with hormone-refractory metastatic prostate cancer.
Prostatic Neoplasms
DRUG: Docetaxel|DRUG: Mitoxantrone|DRUG: Prednisone
Efficacy: Overall survival, From beginning to end of the study|Objective response rate of patients with measurable disease by Response Evaluation Criteria in Solid tumours, From beginning to end of study|Prostatic Specific Antigen response, From the beginning to the end of study|Pain response (McGill-Melzack Scale), From beginning to end of study|Time to progression, From beginning to end of study|Adverse event, From beginning to end of study|Quality Of Life: Functional assessment of chronic illness therapy-prostate questionnaire will be used, From beginning to end of study
To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and prednisone in subjects with hormone-refractory metastatic prostate cancer.